Association of socioeconomic disadvantage and neighborhood disparities with clinical outcomes in multiple sclerosis patients.

Area deprivation index Multiple sclerosis Neighborhood-level disadvantage Quality of life in neurological disorders Socioeconomic disadvantage

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
May 2022
Historique:
received: 14 11 2021
revised: 20 01 2022
accepted: 10 03 2022
pubmed: 8 4 2022
medline: 9 6 2022
entrez: 7 4 2022
Statut: ppublish

Résumé

Socioeconomic disadvantage may be an important contributor to clinical outcomes in MS but is not well understood. Our objective was to examine the associations between Area Deprivation Index (ADI), a validated measure of neighborhood-level disadvantage, with clinical outcomes. We assessed the longitudinal association between MS Performance Test (MSPT) and quality of life in Neurological Disorders (Neuro-QoL) measures with ADI quartiles (Q1: lowest deprivation - Q4 highest deprivation) in relapsing remitting MS (RRMS) and progressive MS cohorts. Our study included 2,921 patients (65.8% RRMS and 34.1% progressive MS) with 13,715 visits. Patients living in the most disadvantaged areas had almost universal worsening on baseline MSPT and Neuro-QoL scores (p < 0.05) when compared to patients living in areas of lowest deprivation. Manual Dexterity Test (MDT) illustrated particular disparity as RRMS patients living in the greatest area of deprivation had MDT score which averaged 2.9 seconds longer than someone living in areas of least deprivation. Longitudinal analysis illustrated less favorable MSPT and Neuro-QoL outcomes across visits between Q1 versus Q4 ADI quartiles within in the RRMS cohort but not within the progressive MS cohort. After adjustment, linearly increasing area deprivation scores reflected less favorable Processing Speed Test (PST) and six Neuro-QoL outcomes among the RRMS cohort. Within the progressive cohort, higher deprivation was associated less favorable MDT, PST and 11 of 12 Neuro-QoL outcome measures. This study provides evidence for socioeconomic disadvantage as a risk factor for disability accrual in MS and may be targeted to improve care while informing resource allocation.

Sections du résumé

BACKGROUND BACKGROUND
Socioeconomic disadvantage may be an important contributor to clinical outcomes in MS but is not well understood. Our objective was to examine the associations between Area Deprivation Index (ADI), a validated measure of neighborhood-level disadvantage, with clinical outcomes.
METHODS METHODS
We assessed the longitudinal association between MS Performance Test (MSPT) and quality of life in Neurological Disorders (Neuro-QoL) measures with ADI quartiles (Q1: lowest deprivation - Q4 highest deprivation) in relapsing remitting MS (RRMS) and progressive MS cohorts.
RESULTS RESULTS
Our study included 2,921 patients (65.8% RRMS and 34.1% progressive MS) with 13,715 visits. Patients living in the most disadvantaged areas had almost universal worsening on baseline MSPT and Neuro-QoL scores (p < 0.05) when compared to patients living in areas of lowest deprivation. Manual Dexterity Test (MDT) illustrated particular disparity as RRMS patients living in the greatest area of deprivation had MDT score which averaged 2.9 seconds longer than someone living in areas of least deprivation. Longitudinal analysis illustrated less favorable MSPT and Neuro-QoL outcomes across visits between Q1 versus Q4 ADI quartiles within in the RRMS cohort but not within the progressive MS cohort. After adjustment, linearly increasing area deprivation scores reflected less favorable Processing Speed Test (PST) and six Neuro-QoL outcomes among the RRMS cohort. Within the progressive cohort, higher deprivation was associated less favorable MDT, PST and 11 of 12 Neuro-QoL outcome measures.
CONCLUSIONS CONCLUSIONS
This study provides evidence for socioeconomic disadvantage as a risk factor for disability accrual in MS and may be targeted to improve care while informing resource allocation.

Identifiants

pubmed: 35390593
pii: S2211-0348(22)00249-8
doi: 10.1016/j.msard.2022.103734
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103734

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Justin R Abbatemarco (JR)

Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, 9500 Euclid Avenue U10, Cleveland, OH 44195, USA.

Alise Carlson (A)

Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, 9500 Euclid Avenue U10, Cleveland, OH 44195, USA.

Daniel Ontaneda (D)

Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, 9500 Euclid Avenue U10, Cleveland, OH 44195, USA; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.

Marisa McGinley (M)

Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, 9500 Euclid Avenue U10, Cleveland, OH 44195, USA; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.

Robert A Bermel (RA)

Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, 9500 Euclid Avenue U10, Cleveland, OH 44195, USA; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.

Scott Husak (S)

Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, USA.

David Bruckman (D)

Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, USA; Center for Populations Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

Jesse D Schold (JD)

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA; Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, USA; Center for Populations Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

Deborah M Miller (DM)

Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, 9500 Euclid Avenue U10, Cleveland, OH 44195, USA; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA. Electronic address: Millerd@ccf.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH